Bausch + Lomb reportedly will acquire ISTA Pharmaceuticals, Inc., for approximately $500 million, a transaction approved by the boards of both companies. The deal should close by summer. The purchase adds ISTA's portfolio of non-steroidal, anti-inflammatory, allergy, glaucoma and spreading agents to Bausch + Lomb's portfolio of Rx ophthalmology and OTC eye health products. In the development pipeline, ISTA has candidates for the treatment of various ocular conditions including inflammation and pain, while Bausch + Lomb's pipeline includes a new class of ocular anti-inflammatory agents and an approach to reducing intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension.Read more.
No comments:
Post a Comment